A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the cytogenetic response to Dasatinib (BMS-354825) administered
for 24 weeks in subjects with Imatinib resistant or intolerant chronic phase chronic myeloid
leukemia (CML) once daily (QD) or twice daily. (BID)